Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1
Neuroblastoma breakpoint family, member 1 (NBPF1), appears to be a double-edged sword with regard to its role in carcinogenesis. On the one hand, the tumor-suppressing functions of NBPF1 have been definitively observed in neuroblastoma, prostate cancer, cutaneous squamous cell carcinoma, and cervica...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.950326/full |
| _version_ | 1828182285632929792 |
|---|---|
| author | Lei Li Sen Chen Yueming Tang Jie Wu Yangzhige He Ling Qiu Ling Qiu |
| author_facet | Lei Li Sen Chen Yueming Tang Jie Wu Yangzhige He Ling Qiu Ling Qiu |
| author_sort | Lei Li |
| collection | DOAJ |
| description | Neuroblastoma breakpoint family, member 1 (NBPF1), appears to be a double-edged sword with regard to its role in carcinogenesis. On the one hand, the tumor-suppressing functions of NBPF1 have been definitively observed in neuroblastoma, prostate cancer, cutaneous squamous cell carcinoma, and cervical cancer. On the other hand, there is evidence that NBPF1 regulates the colony formation, invasion, and maintenance of liver cancer cells and hence functions as an oncogene. The roles of NBPF1 are strictly dependent on the biological context and type of organization. However, a systematic pan-cancer analysis has thus far not been undertaken, and the significance of NBPF1 in the occurrence and progression of many malignancies is uncertain. In this paper, bioinformatics techniques were employed to analyze NBPF1 expression across different cancers and investigate the relationship between NBPF1 and clinical features, prognosis, genetic alteration, and tumor immune microenvironment, respectively. Our results show that NBPF1 is variably expressed in distinct tumor tissues and is also closely linked to clinical outcomes. In particular, compared to other tumor types, there was a strong negative correlation between NBPF1 expression and various components of the tumor microenvironment in adrenocortical carcinoma (ACC). We thus developed an NBPF1-derived immune risk model based on NBPF1-related immune genes; ACC patients with a high-risk score tended to have a poorer prognosis, accompanied by immune hyporesponsiveness. NBPF1 can be used as a prognostic biomarker for multiple cancers. Moreover, anti-NBPF1 immunotherapy may be suitable for treating ACC patients. |
| first_indexed | 2024-04-12T06:16:04Z |
| format | Article |
| id | doaj.art-7deecc315cbf405cae059abce64dc0f6 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T06:16:04Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-7deecc315cbf405cae059abce64dc0f62022-12-22T03:44:30ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-08-011310.3389/fendo.2022.950326950326Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1Lei Li0Sen Chen1Yueming Tang2Jie Wu3Yangzhige He4Ling Qiu5Ling Qiu6Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, ChinaImmune Cells and Antibody Engineering Research Center of Guizhou Province, Key Laboratory of Biology and Medical Engineering, School of Biology and Engineering, Guizhou Medical University, Guiyang, ChinaDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, ChinaDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, ChinaDepartment of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, ChinaState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, ChinaNeuroblastoma breakpoint family, member 1 (NBPF1), appears to be a double-edged sword with regard to its role in carcinogenesis. On the one hand, the tumor-suppressing functions of NBPF1 have been definitively observed in neuroblastoma, prostate cancer, cutaneous squamous cell carcinoma, and cervical cancer. On the other hand, there is evidence that NBPF1 regulates the colony formation, invasion, and maintenance of liver cancer cells and hence functions as an oncogene. The roles of NBPF1 are strictly dependent on the biological context and type of organization. However, a systematic pan-cancer analysis has thus far not been undertaken, and the significance of NBPF1 in the occurrence and progression of many malignancies is uncertain. In this paper, bioinformatics techniques were employed to analyze NBPF1 expression across different cancers and investigate the relationship between NBPF1 and clinical features, prognosis, genetic alteration, and tumor immune microenvironment, respectively. Our results show that NBPF1 is variably expressed in distinct tumor tissues and is also closely linked to clinical outcomes. In particular, compared to other tumor types, there was a strong negative correlation between NBPF1 expression and various components of the tumor microenvironment in adrenocortical carcinoma (ACC). We thus developed an NBPF1-derived immune risk model based on NBPF1-related immune genes; ACC patients with a high-risk score tended to have a poorer prognosis, accompanied by immune hyporesponsiveness. NBPF1 can be used as a prognostic biomarker for multiple cancers. Moreover, anti-NBPF1 immunotherapy may be suitable for treating ACC patients.https://www.frontiersin.org/articles/10.3389/fendo.2022.950326/fullNBPF1pan-cancer analysisadrenocortical carcinomaimmunebiomarker |
| spellingShingle | Lei Li Sen Chen Yueming Tang Jie Wu Yangzhige He Ling Qiu Ling Qiu Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 Frontiers in Endocrinology NBPF1 pan-cancer analysis adrenocortical carcinoma immune biomarker |
| title | Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 |
| title_full | Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 |
| title_fullStr | Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 |
| title_full_unstemmed | Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 |
| title_short | Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1 |
| title_sort | oncogene or tumor suppressor gene an integrated pan cancer analysis of nbpf1 |
| topic | NBPF1 pan-cancer analysis adrenocortical carcinoma immune biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.950326/full |
| work_keys_str_mv | AT leili oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT senchen oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT yuemingtang oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT jiewu oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT yangzhigehe oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT lingqiu oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 AT lingqiu oncogeneortumorsuppressorgeneanintegratedpancanceranalysisofnbpf1 |